Correlation between severe infection and breast cancer metastases in the EORTC 10994/BIG 1-00 trial: Investigating innate immunity as a tumour suppressor in breast cancer.
Identifieur interne : 001095 ( PubMed/Corpus ); précédent : 001094; suivant : 001096Correlation between severe infection and breast cancer metastases in the EORTC 10994/BIG 1-00 trial: Investigating innate immunity as a tumour suppressor in breast cancer.
Auteurs : Nathan Touati ; Konstantinos Tryfonidis ; Franco Caramia ; Hervé Bonnefoi ; David Cameron ; Leen Slaets ; Belinda S. Parker ; Sherene LoiSource :
- European journal of cancer (Oxford, England : 1990) [ 1879-0852 ] ; 2017.
English descriptors
- KwdEn :
- Adult, Aged, Bone Density Conservation Agents (therapeutic use), Bone Neoplasms (epidemiology), Bone Neoplasms (secondary), Breast Neoplasms (drug therapy), Breast Neoplasms (immunology), Breast Neoplasms (metabolism), Breast Neoplasms (pathology), Chemotherapy, Adjuvant, Denosumab (therapeutic use), Febrile Neutropenia (immunology), Female, Follow-Up Studies, Humans, Immunity, Innate (physiology), Incidence, Infection (immunology), Interferon Regulatory Factor-7 (immunology), Interferon Regulatory Factor-7 (metabolism), Middle Aged, Neoplasm Metastasis (immunology), Regression Analysis.
- MESH :
- chemical , immunology : Interferon Regulatory Factor-7.
- chemical , metabolism : Interferon Regulatory Factor-7.
- chemical , therapeutic use : Bone Density Conservation Agents, Denosumab.
- drug therapy : Breast Neoplasms.
- epidemiology : Bone Neoplasms.
- immunology : Breast Neoplasms, Febrile Neutropenia, Infection, Neoplasm Metastasis.
- metabolism : Breast Neoplasms.
- pathology : Breast Neoplasms.
- physiology : Immunity, Innate.
- secondary : Bone Neoplasms.
- Adult, Aged, Chemotherapy, Adjuvant, Female, Follow-Up Studies, Humans, Incidence, Middle Aged, Regression Analysis.
Abstract
Breast cancer cells which express an innate immune signature regulated by interferon regulatory factor 7 (IRF7) have reduced metastatic potential. Infections can induce interferon signalling and may activate an anti-tumour immune response. We investigated whether 'severe infection' can be a clinical surrogate of this phenomenon and/or the presence of high levels of the IRF7 signature at diagnosis before neo-adjuvant chemotherapy (NACT) is associated with a reduced distant relapse risk, specifically in bones.
DOI: 10.1016/j.ejca.2016.11.015
PubMed: 28027521
Links to Exploration step
pubmed:28027521Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Correlation between severe infection and breast cancer metastases in the EORTC 10994/BIG 1-00 trial: Investigating innate immunity as a tumour suppressor in breast cancer.</title><author><name sortKey="Touati, Nathan" sort="Touati, Nathan" uniqKey="Touati N" first="Nathan" last="Touati">Nathan Touati</name><affiliation><nlm:affiliation>EORTC, Statistics Department, Avenue Emmanuel Mounier 83b11, 1200 Brussels, Belgium. Electronic address: nathan.touati@eortc.be.</nlm:affiliation></affiliation></author><author><name sortKey="Tryfonidis, Konstantinos" sort="Tryfonidis, Konstantinos" uniqKey="Tryfonidis K" first="Konstantinos" last="Tryfonidis">Konstantinos Tryfonidis</name><affiliation><nlm:affiliation>EORTC, Medical Department, Avenue Emmanuel Mounier 83b11, 1200 Brussels, Belgium. Electronic address: Konstantinos.tryfonidis@eortc.be.</nlm:affiliation></affiliation></author><author><name sortKey="Caramia, Franco" sort="Caramia, Franco" uniqKey="Caramia F" first="Franco" last="Caramia">Franco Caramia</name><affiliation><nlm:affiliation>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia. Electronic address: Franco.Caramia@petermac.org.</nlm:affiliation></affiliation></author><author><name sortKey="Bonnefoi, Herve" sort="Bonnefoi, Herve" uniqKey="Bonnefoi H" first="Hervé" last="Bonnefoi">Hervé Bonnefoi</name><affiliation><nlm:affiliation>Department of Medical Oncology, Institut Bergonié Unicancer, INSERM CIC1401, Bordeaux, France. Electronic address: H.Bonnefoi@bordeaux.unicancer.fr.</nlm:affiliation></affiliation></author><author><name sortKey="Cameron, David" sort="Cameron, David" uniqKey="Cameron D" first="David" last="Cameron">David Cameron</name><affiliation><nlm:affiliation>Western General Hospital, Edinburgh Cancer Centre, Crewe Road South, GB Edinburgh EH4 2XU, UK. Electronic address: D.Cameron@ed.ac.uk.</nlm:affiliation></affiliation></author><author><name sortKey="Slaets, Leen" sort="Slaets, Leen" uniqKey="Slaets L" first="Leen" last="Slaets">Leen Slaets</name><affiliation><nlm:affiliation>EORTC, Statistics Department, Avenue Emmanuel Mounier 83b11, 1200 Brussels, Belgium. Electronic address: leen.slaets@eortc.be.</nlm:affiliation></affiliation></author><author><name sortKey="Parker, Belinda S" sort="Parker, Belinda S" uniqKey="Parker B" first="Belinda S" last="Parker">Belinda S. Parker</name><affiliation><nlm:affiliation>Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Australia. Electronic address: Belinda.Parker@Iatrobe.edu.uk.</nlm:affiliation></affiliation></author><author><name sortKey="Loi, Sherene" sort="Loi, Sherene" uniqKey="Loi S" first="Sherene" last="Loi">Sherene Loi</name><affiliation><nlm:affiliation>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia. Electronic address: sherene.loi@petermac.org.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28027521</idno><idno type="pmid">28027521</idno><idno type="doi">10.1016/j.ejca.2016.11.015</idno><idno type="wicri:Area/PubMed/Corpus">001095</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001095</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Correlation between severe infection and breast cancer metastases in the EORTC 10994/BIG 1-00 trial: Investigating innate immunity as a tumour suppressor in breast cancer.</title><author><name sortKey="Touati, Nathan" sort="Touati, Nathan" uniqKey="Touati N" first="Nathan" last="Touati">Nathan Touati</name><affiliation><nlm:affiliation>EORTC, Statistics Department, Avenue Emmanuel Mounier 83b11, 1200 Brussels, Belgium. Electronic address: nathan.touati@eortc.be.</nlm:affiliation></affiliation></author><author><name sortKey="Tryfonidis, Konstantinos" sort="Tryfonidis, Konstantinos" uniqKey="Tryfonidis K" first="Konstantinos" last="Tryfonidis">Konstantinos Tryfonidis</name><affiliation><nlm:affiliation>EORTC, Medical Department, Avenue Emmanuel Mounier 83b11, 1200 Brussels, Belgium. Electronic address: Konstantinos.tryfonidis@eortc.be.</nlm:affiliation></affiliation></author><author><name sortKey="Caramia, Franco" sort="Caramia, Franco" uniqKey="Caramia F" first="Franco" last="Caramia">Franco Caramia</name><affiliation><nlm:affiliation>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia. Electronic address: Franco.Caramia@petermac.org.</nlm:affiliation></affiliation></author><author><name sortKey="Bonnefoi, Herve" sort="Bonnefoi, Herve" uniqKey="Bonnefoi H" first="Hervé" last="Bonnefoi">Hervé Bonnefoi</name><affiliation><nlm:affiliation>Department of Medical Oncology, Institut Bergonié Unicancer, INSERM CIC1401, Bordeaux, France. Electronic address: H.Bonnefoi@bordeaux.unicancer.fr.</nlm:affiliation></affiliation></author><author><name sortKey="Cameron, David" sort="Cameron, David" uniqKey="Cameron D" first="David" last="Cameron">David Cameron</name><affiliation><nlm:affiliation>Western General Hospital, Edinburgh Cancer Centre, Crewe Road South, GB Edinburgh EH4 2XU, UK. Electronic address: D.Cameron@ed.ac.uk.</nlm:affiliation></affiliation></author><author><name sortKey="Slaets, Leen" sort="Slaets, Leen" uniqKey="Slaets L" first="Leen" last="Slaets">Leen Slaets</name><affiliation><nlm:affiliation>EORTC, Statistics Department, Avenue Emmanuel Mounier 83b11, 1200 Brussels, Belgium. Electronic address: leen.slaets@eortc.be.</nlm:affiliation></affiliation></author><author><name sortKey="Parker, Belinda S" sort="Parker, Belinda S" uniqKey="Parker B" first="Belinda S" last="Parker">Belinda S. Parker</name><affiliation><nlm:affiliation>Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Australia. Electronic address: Belinda.Parker@Iatrobe.edu.uk.</nlm:affiliation></affiliation></author><author><name sortKey="Loi, Sherene" sort="Loi, Sherene" uniqKey="Loi S" first="Sherene" last="Loi">Sherene Loi</name><affiliation><nlm:affiliation>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia. Electronic address: sherene.loi@petermac.org.</nlm:affiliation></affiliation></author></analytic><series><title level="j">European journal of cancer (Oxford, England : 1990)</title><idno type="eISSN">1879-0852</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Bone Density Conservation Agents (therapeutic use)</term><term>Bone Neoplasms (epidemiology)</term><term>Bone Neoplasms (secondary)</term><term>Breast Neoplasms (drug therapy)</term><term>Breast Neoplasms (immunology)</term><term>Breast Neoplasms (metabolism)</term><term>Breast Neoplasms (pathology)</term><term>Chemotherapy, Adjuvant</term><term>Denosumab (therapeutic use)</term><term>Febrile Neutropenia (immunology)</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Immunity, Innate (physiology)</term><term>Incidence</term><term>Infection (immunology)</term><term>Interferon Regulatory Factor-7 (immunology)</term><term>Interferon Regulatory Factor-7 (metabolism)</term><term>Middle Aged</term><term>Neoplasm Metastasis (immunology)</term><term>Regression Analysis</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Interferon Regulatory Factor-7</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Interferon Regulatory Factor-7</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Bone Density Conservation Agents</term><term>Denosumab</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Bone Neoplasms</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Breast Neoplasms</term><term>Febrile Neutropenia</term><term>Infection</term><term>Neoplasm Metastasis</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Immunity, Innate</term></keywords><keywords scheme="MESH" qualifier="secondary" xml:lang="en"><term>Bone Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Chemotherapy, Adjuvant</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Incidence</term><term>Middle Aged</term><term>Regression Analysis</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Breast cancer cells which express an innate immune signature regulated by interferon regulatory factor 7 (IRF7) have reduced metastatic potential. Infections can induce interferon signalling and may activate an anti-tumour immune response. We investigated whether 'severe infection' can be a clinical surrogate of this phenomenon and/or the presence of high levels of the IRF7 signature at diagnosis before neo-adjuvant chemotherapy (NACT) is associated with a reduced distant relapse risk, specifically in bones.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28027521</PMID><DateCreated><Year>2016</Year><Month>12</Month><Day>27</Day></DateCreated><DateCompleted><Year>2017</Year><Month>08</Month><Day>09</Day></DateCompleted><DateRevised><Year>2017</Year><Month>08</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0852</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><PubDate><Year>2017</Year><Month>Feb</Month></PubDate></JournalIssue><Title>European journal of cancer (Oxford, England : 1990)</Title><ISOAbbreviation>Eur. J. Cancer</ISOAbbreviation></Journal><ArticleTitle>Correlation between severe infection and breast cancer metastases in the EORTC 10994/BIG 1-00 trial: Investigating innate immunity as a tumour suppressor in breast cancer.</ArticleTitle><Pagination><MedlinePgn>95-102</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0959-8049(16)32593-X</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejca.2016.11.015</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Breast cancer cells which express an innate immune signature regulated by interferon regulatory factor 7 (IRF7) have reduced metastatic potential. Infections can induce interferon signalling and may activate an anti-tumour immune response. We investigated whether 'severe infection' can be a clinical surrogate of this phenomenon and/or the presence of high levels of the IRF7 signature at diagnosis before neo-adjuvant chemotherapy (NACT) is associated with a reduced distant relapse risk, specifically in bones.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Clinical data of the European Organisation for Research and Treatment of Cancer 10994/BIG 1-00 phase III trial which randomised 1856 patients treated with NACT between 2001 and 2006, were used. Severe infection was febrile neutropenia or any other grade III-IV infective adverse event during NACT. The IRF7 signature was calculated from gene expression data available for 160 patients on a pre-NACT biopsy. Cox models for distant relapse-free interval (DRFI) investigated the effect of the severe infection and IRF7. Fine and Gray models studied the occurrence of bone metastases as first distant relapse.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Median follow-up was 4.8 years. No association between severe infection and DFRI was observed in the entire population (n = 1615 eligible patients) hazard ratio [(HR] = 0.99, 90% CI, confidence interval [CI] = 0.81-1.20). For IRF7 (N = 160), a trend towards an association with DRFI was observed (HR = 0.89 for a 50 unit increase, 90% CI = 0.78-1.02, p = 0.081). Higher levels of the IRF7 signature were significantly associated with a decreased bone metastases risk: (HR = 0.76 for a 50 unit increase, 95% CI, 0.62-0.94, p = 0.012).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In this study it was shown that severe infection during NACT was not associated with decreased DRFI while high expression of the IRF7 gene signature was significantly associated with reduced bone relapse. This result may be useful for future adjuvant bisphosphonate/denosumab use.</AbstractText><CopyrightInformation>Copyright © 2016 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Touati</LastName><ForeName>Nathan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>EORTC, Statistics Department, Avenue Emmanuel Mounier 83b11, 1200 Brussels, Belgium. Electronic address: nathan.touati@eortc.be.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tryfonidis</LastName><ForeName>Konstantinos</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>EORTC, Medical Department, Avenue Emmanuel Mounier 83b11, 1200 Brussels, Belgium. Electronic address: Konstantinos.tryfonidis@eortc.be.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caramia</LastName><ForeName>Franco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia. Electronic address: Franco.Caramia@petermac.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonnefoi</LastName><ForeName>Hervé</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Institut Bergonié Unicancer, INSERM CIC1401, Bordeaux, France. Electronic address: H.Bonnefoi@bordeaux.unicancer.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cameron</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Western General Hospital, Edinburgh Cancer Centre, Crewe Road South, GB Edinburgh EH4 2XU, UK. Electronic address: D.Cameron@ed.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Slaets</LastName><ForeName>Leen</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>EORTC, Statistics Department, Avenue Emmanuel Mounier 83b11, 1200 Brussels, Belgium. Electronic address: leen.slaets@eortc.be.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parker</LastName><ForeName>Belinda S</ForeName><Initials>BS</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Australia. Electronic address: Belinda.Parker@Iatrobe.edu.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loi</LastName><ForeName>Sherene</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia. Electronic address: sherene.loi@petermac.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>12</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Cancer</MedlineTA><NlmUniqueID>9005373</NlmUniqueID><ISSNLinking>0959-8049</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050071">Bone Density Conservation Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050839">Interferon Regulatory Factor-7</NameOfSubstance></Chemical><Chemical><RegistryNumber>4EQZ6YO2HI</RegistryNumber><NameOfSubstance UI="D000069448">Denosumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050071" MajorTopicYN="N">Bone Density Conservation Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001859" MajorTopicYN="N">Bone Neoplasms</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000556" MajorTopicYN="Y">secondary</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017024" MajorTopicYN="N">Chemotherapy, Adjuvant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069448" MajorTopicYN="N">Denosumab</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064147" MajorTopicYN="N">Febrile Neutropenia</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007239" MajorTopicYN="N">Infection</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050839" MajorTopicYN="N">Interferon Regulatory Factor-7</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012044" MajorTopicYN="N">Regression Analysis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bone metastases</Keyword><Keyword MajorTopicYN="N">Breast cancer</Keyword><Keyword MajorTopicYN="N">IRF7 signature</Keyword><Keyword MajorTopicYN="N">Immune response</Keyword><Keyword MajorTopicYN="N">Neo-adjuvant chemotherapy</Keyword><Keyword MajorTopicYN="N">Severe infection</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>09</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>11</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>12</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>12</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28027521</ArticleId><ArticleId IdType="pii">S0959-8049(16)32593-X</ArticleId><ArticleId IdType="doi">10.1016/j.ejca.2016.11.015</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001095 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001095 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:28027521
|texte= Correlation between severe infection and breast cancer metastases in the EORTC 10994/BIG 1-00 trial: Investigating innate immunity as a tumour suppressor in breast cancer.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:28027521" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |